Financial reports
Current reports
8-K
Completion of Acquisition or Disposition of Assets
15 Mar 21
8-K
Departure of Directors or Certain Officers
4 Mar 21
8-K
Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
1 Mar 21
8-K
Results of Operations and Financial Condition
16 Feb 21
8-K
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
1 Feb 21
8-K
Departure of Directors or Certain Officers
8 Dec 20
8-K
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
10 Nov 20
8-K
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
5 Nov 20
8-K
Departure of Directors or Certain Officers
15 Sep 20
8-K
Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
12 Aug 20
Registration and prospectus
15-12B
Securities registration termination
25 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Mar 21
POSASR
Automatic shelf registration (post-effective amendment)
15 Mar 21
SC 14D9/A
Tender offer solicitation (amended)
15 Mar 21
25-NSE
Exchange delisting
15 Mar 21
SC TO-T/A
Third party tender offer statement (amended)
15 Mar 21
SC TO-T/A
Third party tender offer statement (amended)
12 Mar 21
SC 14D9/A
Tender offer solicitation (amended)
12 Mar 21
SC 14D9/A
Tender offer solicitation (amended)
8 Mar 21
Other
UPLOAD
Letter from SEC
3 Mar 21
CORRESP
Correspondence with SEC
3 Mar 21
UPLOAD
Letter from SEC
1 Mar 21
UPLOAD
Letter from SEC
1 Mar 21
EFFECT
Notice of effectiveness
28 May 20
CORRESP
Correspondence with SEC
26 May 20
CORRESP
Correspondence with SEC
26 May 20
UPLOAD
Letter from SEC
17 Apr 20
EFFECT
Notice of effectiveness
3 Oct 19
CERT
Certification of approval for exchange listing
30 Sep 19
Ownership
SC 13D/A
Boundless Meadow Ltd
17 Mar 21
4
Yanling Cao
16 Mar 21
4
Tyrell Rivers
16 Mar 21
4
Change in insider ownership
16 Mar 21
4
Andreas Wicki
15 Mar 21
4
Edward Hu
15 Mar 21
4
Capital Opportunities Master Fund Boyu
15 Mar 21
4
Mitchell Chan
15 Mar 21
4
Jorn Drappa
15 Mar 21
4
James Paul Kastenmayer
15 Mar 21